Harrow Health Inc (HROW)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.09B
Last updated: Nov 17, 2026 at 4:24 PM ET
Harrow Health Inc (HROW) Stock Chart
Harrow Health (HROW) has a latest price of $29.52 on Nov 17, 2026, 46.2% below its 52-week high of $54.85. Its price fell 27.6% over the past 12 months. The month-end price rose 951.8% over the 10 years through Oct 2026, a compound annual rate of 26.5%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $54.18 in Feb 2026 and its lowest $1.50 in Oct 2017, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart HROW with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for HROW.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 29.1%, and over 6 months it fell 3.8%. The month-end price rose 97.0% over the 3 years through Oct 2026, a compound annual rate of 25.4%.
| Period | Change |
|---|---|
| 1 month | +6.6% |
| 3 months | -29.1% |
| 6 months | -3.8% |
| 12 months | -27.6% |
| 12 months, with dividends | -27.6% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +97.0% | +25.4% |
| 5 years | +179.9% | +22.9% |
| 10 years | +951.8% | +26.5% |
Price by Year
Its best calendar year was 2018, when the price rose 234.7%, and its weakest was 2017, when it fell 32.0%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $28.24 | -42.4% |
| 2025 | $49.00 | +46.1% |
| 2024 | $33.55 | +199.6% |
| 2023 | $11.20 | -24.1% |
| 2022 | $14.76 | +70.8% |
| 2021 | $8.64 | +25.9% |
| 2020 | $6.86 | -11.8% |
| 2019 | $7.78 | +36.7% |
| 2018 | $5.69 | +234.7% |
| 2017 | $1.70 | -32.0% |
Trading Range
The price is 3.0% below its 50-day average of $30.42 and 21.0% below its 200-day average of $37.37.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $29.52 | |
| 52-week high | $54.85 | -46.2% |
| 52-week low | $25.76 | +14.6% |
| 50-day average | $30.42 | -3.0% |
| 200-day average | $37.37 | -21.0% |
Price Risk
Over 3 years, its largest fall from a peak was 61.4%.
| Measure | Value |
|---|---|
| 1-year beta | 1.42 |
| Largest fall, 1 year | -52.5% |
| Largest fall, 3 years | -61.4% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About HROW
What is HROW's 1-year price change?
Harrow Health's price fell 27.6% over the past 12 months. With dividends included, the 12-month total return was -27.6%.
What is HROW's 5-year price change?
Harrow Health's month-end price rose 179.9% over the 5 years through Oct 2026, a compound annual rate of 22.9%. These figures leave out dividends.
What is HROW's 52-week high and low?
Harrow Health's 52-week high is $54.85 and its 52-week low is $25.76. Its latest price of $29.52 on Nov 17, 2026 is 46.2% below the high.
What is HROW's beta?
Harrow Health's 1-year beta against the S&P 500 is 1.42, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 52.5%.
Is the HROW chart free?
Yes. Advanced Charting for HROW is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
HROW pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors